Literature DB >> 3470281

In-vitro selection of bacteria resistant to the 4-quinolone agents.

D I Limb, D J Dabbs, R C Spencer.   

Abstract

The activity of five 4-quinolone agents: norfloxacin, ciprofloxacin, ofloxacin, enoxacin and pefloxacin was tested against 121 distinct clinical bacterial isolates. Ciprofloxacin was the most active agent against Gram-negative bacteria and streptococci and pefloxacin was the most active against staphylococci. By serial sub-culture in sub-inhibitory concentrations of antibiotic we were able to select resistance in almost all Gram-positive and Gram-negative species, with the exception of Escherichia coli. Resistance to norfloxacin was more readily produced than resistance to the other four agents. There was almost complete cross-resistance among the five agents tested. The proportional increases in MIC were higher in Gram-negative than in Gram-positive organisms.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3470281     DOI: 10.1093/jac/19.1.65

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  18 in total

1.  First clinical isolate of highly fluoroquinolone-resistant Escherichia coli in Scandanavia.

Authors:  M Jonsson; M Walder; A Forsgren
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-11       Impact factor: 3.267

2.  Antagonism of wild-type and resistant Escherichia coli and its DNA gyrase by the tricyclic 4-quinolone analogs ofloxacin and S-25930 stereoisomers.

Authors:  J S Wolfson; D C Hooper; E Y Ng; K S Souza; G L McHugh; M N Swartz
Journal:  Antimicrob Agents Chemother       Date:  1987-11       Impact factor: 5.191

3.  Development of resistance to ciprofloxacin in nutrient-rich and nutrient-limited growth conditions in vitro by Pseudomonas aeruginosa isolates from patients with cystic fibrosis.

Authors:  M I Ferguson; E M Scott; P S Collier
Journal:  Antimicrob Agents Chemother       Date:  1991-12       Impact factor: 5.191

4.  Isolation of fluoroquinolone-resistant Escherichia coli and Klebsiella pneumoniae from an infected Hickman catheter.

Authors:  M López-Brea; T Alarcón
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-05       Impact factor: 3.267

5.  Cross-resistance and cross-susceptibility between fluoroquinolone agents.

Authors:  A L Barry; P C Fuchs
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

6.  Studies on the emergence of resistance to lomefloxacin in vitro.

Authors:  M Kanematsu; D Greenwood
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-08       Impact factor: 3.267

7.  Increasing rates of in vitro resistance to ciprofloxacin and norfloxacin in isolates from urine specimens.

Authors:  D Desgrandchamps; J Munzinger
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

8.  Cloning and nucleotide sequence of Mycobacterium tuberculosis gyrA and gyrB genes and detection of quinolone resistance mutations.

Authors:  H E Takiff; L Salazar; C Guerrero; W Philipp; W M Huang; B Kreiswirth; S T Cole; W R Jacobs; A Telenti
Journal:  Antimicrob Agents Chemother       Date:  1994-04       Impact factor: 5.191

Review 9.  Pefloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  J P Gonzalez; J M Henwood
Journal:  Drugs       Date:  1989-05       Impact factor: 9.546

Review 10.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.